Anxiety/OCD:
Indications for: Trifluoperazine
Short-term (up to 12 weeks) treatment of nonpsychotic anxiety.
Adult Dosage:
1–2mg twice daily; max 6mg/day.
Children Dosage:
Not recommended.
Trifluoperazine Contraindications:
Coma. CNS or bone marrow depression. Blood dyscrasias. Liver disease.
Trifluoperazine Warnings/Precautions:
Discontinue 48 hrs before to at least 24 hrs after myelography. Cardiovascular disease. Epilepsy. Glaucoma. History of breast cancer. Exposure to extreme heat. Monitor blood, liver, and ocular function. Mental retardation. Elderly. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester pregnancy). Pregnancy, nursing mothers: not recommended.
Trifluoperazine Classification:
Phenothiazine.
Trifluoperazine Interactions:
Potentiates CNS depression with alcohol, other CNS depressants. Potentiates phenytoin, propranolol, α-blockers. May be potentiated by propranolol. Antagonizes guanethidine, oral anticoagulants. Antagonized by anticholinergics. Orthostatic hypotension with thiazides. May cause false (+) PKU test. Adjust antiepileptic drugs.
Adverse Reactions:
Tardive dyskinesia, drowsiness, blood dyscrasias, jaundice, hypotension, retinopathy, may mask emetic signs of disease, lowered seizure threshold, rash, anticholinergic effects, insomnia, extrapyramidal reactions, agitation, photosensitivity, neuroleptic malignant syndrome.
Note:
Formerly known under the brand name Stelazine.
How Supplied:
Contact supplier.
Psychosis:
Indications for: Trifluoperazine
Psychosis.
Adult Dosage:
Initially: 2–5mg twice daily. Usual range: 15–20mg/day.
Children Dosage:
<6yrs: not recommended. ≥6yrs (under close supervision): initially 1mg 1–2 times a day. Usual max 15mg/day.
Trifluoperazine Contraindications:
Coma. CNS or bone marrow depression. Blood dyscrasias. Liver disease.
Trifluoperazine Warnings/Precautions:
Discontinue at least 48 hrs before to at least 24 hrs after myelography. Cardiovascular disease. Epilepsy. Glaucoma. History of breast cancer. Exposure to extreme heat. Monitor blood, liver, and visual function. Mental retardation. Elderly. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester pregnancy). Pregnancy, nursing mothers: not recommended.
Trifluoperazine Classification:
Piperazine phenothiazine.
Trifluoperazine Interactions:
Potentiates CNS depression with alcohol, other CNS depressants. Potentiates phenytoin, propranolol, α-blockers. May be potentiated by propranolol. Antagonizes guanethidine, oral anticoagulants. Antagonized by anticholinergics. Orthostatic hypotension with thiazides. May cause false (+) PKU test. Adjust antiepileptic drugs.
Adverse Reactions:
Tardive dyskinesia, drowsiness, blood dyscrasias, jaundice, hypotension, retinopathy, may mask emetic signs of disease, lowered seizure threshold, rash, anticholinergic effects, insomnia, extrapyramidal reactions, agitation, photosensitivity, neuroleptic malignant syndrome.
How Supplied:
Contact supplier.
